Sale to NuVasive, Inc.
Baird served as the exclusive financial advisor to Impulse Monitoring, Inc., a portfolio company of Tullis Health Investors and Ascension Health Ventures
AboutImpulse Monitoring, Inc. (“IMI” or the “Company”) has been acquired by NuVasive, Inc. (“NuVasive”) (NASDAQ: NUVA) for $80 million, comprised of $40 million in cash and $40 million in stock.
Headquartered in Columbia, Maryland, IMI is a leading service-based provider of outsourced intraoperative neuromonitoring (“IONM”) solutions for spinal, nerve and brain-related surgeries, and autotransfusion services. IMI’s outsourced IONM solutions are provided to surgeons, hospitals and medical centers, staffed by physicians and certified neurophysiologists who monitor the nervous system during surgery via broadband transmission in real-time. The Company supports a strong roster of blue chip clients, currently serving over 214 leading hospitals and 854 surgeons in 23 states and the District of Columbia. IMI is backed by Tullis Health Investors and Ascension Health Ventures.
Tullis Health Investors is a family of funds that invests primarily in established healthcare companies, focusing on the biotechnology and life science, pharmaceuticals, healthcare services and medical devices sectors.
Ascension Health Ventures is a strategic healthcare venture fund, with $325 million under management, focused on expansion- to late-stage companies in the medical device, technology and service sectors.
NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedures for the spine. NuVasive currently sells products used in a wide variety of spinal surgeries and is best known for its Maximum Access Surgery (MAS) platform that allows surgeons to perform minimally disruptive procedures.
For additional information about this transaction, please contact:
- October 2011
- Impulse Monitoring, Inc.
- Target Location
- North America
- Acquiror Location
- North America